Mariana Oncology’s Post

Exciting data presented by the Mariana Oncology, a Novartis company, team at the 36th EORTC-NCI-AACR Symposium today! Building upon the data presented at #ESMO2024, which demonstrated a favorable preclinical biodistribution profile, the #ENA2024 results emphasize the activity of our DLL3-targeted radioligand therapy in several tumor models, including those with low DLL3 expression levels. (Poster ENA24-152) The results reinforce the potential of our precise approach to radiopharmaceutical design, in which we apply focused optimization to each component to yield compounds with holistic properties ideal for selective tumor engagement and destruction. #RLT #radioligandtherapy #oncology #drugdevelopment

Unraveling the BRCA1 Connection: A Crucial Step in Breast Cancer Research BRCA1, a critical tumor suppressor, plays a pivotal role in breast cancer development. Mutations in BRCA1 can significantly increase the risk of the disease, making it a crucial area of focus for researchers. Our advanced tools can empower you to delve deeper into BRCA1's function, potentially leading to groundbreaking discoveries and innovative therapeutic strategies. Click here to learn more: https://lnkd.in/eSUmYFJj #breastcancer #cancerresearch #BRCA1 #biotech #oncology #researchtools

📣 There is still time to submit your paper to our Topic Collection: Nanomedicine in Oncology. Reach a wide international audience through our open access publication model, and receive a 25% discount on the Article Processing Charge. 🌎 This collection will ✔️ Bring together the most recent research on nanomedicine in cancer therapy and diagnosis and their potential applications in clinical translation ✔️ Present current advances in nanobiotechnology in improving cancer immunotherapy ✔️ Include nanobiotechnology in monitoring immune responses, which would guide clinical practice Submit by 29th March 2024: https://bit.ly/3TjbDml #oncology #cancertreatment #cancerresearch #oncologyresearch

Could ADCs be a game-changer for oncology? New cancer drugs based on ADCs have shown promising results in shrinking hard-to-treat tumors in mice. This innovative therapy targets cancer cells' waste disposal system, leading to their self-destruction. 3 Key Takeaways: - This approach disrupts a novel cellular process, offering a fresh perspective on cancer treatment. - Early results in mice are encouraging, but further research is needed to assess safety and efficacy in humans. - This discovery highlights the continuous advancements in cancer research, offering hope for future breakthroughs. What are your thoughts on this new therapeutic approach? #LifeSciences #Oncology #CancerResearch #DrugDiscovery #Innovation #Breakthrough https://lnkd.in/eY-Bnrqf

In the ever-evolving field of oncology, targeted therapies for Non-Small Cell Lung Cancer (NSCLC) are reshaping our approach to treatment. As a researcher working alongside many pharma clients and attending several International conferences, I tried to summarise some of the latest advancements, ongoing challenges, and promising potential of these therapies in my newest article. Join me in examining how these innovations are poised to improve patient outcomes and redefine the landscape of cancer care. Read more by clicking the link below. #Oncology #Ipsos #NSCLC

The ENZA-p study, leaded by Louise Emmett, Ian Davis & ANZUP Cancer Trials Group Limited team, evaluated the efficacy and safety of combining enzalutamide with [¹⁷⁷Lu]Lu-PSMA-617 versus enzalutamide alone as first-line treatment for metastatic castration-resistant prostate cancer. Check out this research that seeks to optimize therapy for metastatic castration-resistant prostate cancer. Stay tuned for insights into enhancing patient outcomes in this challenging condition. https://buff.ly/4aZ2Pcs #prostatecancer #radiotheranostics #nuclearmedicine #cancerawareness

This is what #clincialimpact looks like. Phase 2 trial testing efficacy and safety of combining enzalutamide with [¹⁷⁷Lu]Lu-PSMA-617 versus enzalutamide alone as first-line treatment for metastatic castration-resistant prostate cancer. While more investigation is required in larger trials for metastatic prostate cancer, these promising results show a nearly doubling of PSA progression free survival with the combination treatment compared to enzalutamide alone. ANZUP Cancer Trials Group Limited Louise Emmett Ian Davis If you want to help support our incredible organisation conduct more practice changing collaborative clinical trials please contact us: https://lnkd.in/gWkwhWJW or email at anzup@anzup.org.au #cancertrials #prostatecancer #belowthebelt NHMRC Clinical Trials Centre Prostate Cancer Research Alliance Movember Cancer Australia Endocyte Novartis Astellas Pharma artnet St Vincent’s Clinic Foundation Roy Morgan Research GenesisCare ANSTO MIM Software Nearly 35,000 people in Australia and over 5,500 people in New Zealand are diagnosed by a Below the Belt cancer (kidney, bladder, prostate, testicular and penile) every year. ANZUP’s mission is to improve the lives of all people affected by Below the Belt Cancers through practice-changing multidisciplinary collaborative clinical trials.

Come and Run together at #ENA 2024, in Barcelona, welcome to drop by our posters to talk about Biology Building Blocks: 1, #PARP1 inhibitor resistant cell line generation and DDR cell panel development 2, High-Throughput 2D and 3D #Cell #Panel screening to facilitate RAS target drug Discovery and development 3, #KAT6A inhibitor screening cascade to facilitate novel drug discovery 4, #METTL3 inhibitors screening cascade for new drug discovery 5, The establishment of #AR cell-based and biochemical assays facilitates novel drug discovery in prostate cancer and breast cancer  6, A #WRN screening cascade to facilitate novel drug discovery #Target #Assay #Technology #DrugScreening #IntegrateBiology platform

Exciting news from UCL researchers! A groundbreaking immunotherapy using gamma-delta T cells shows promise in treating osteosarcoma and bone metastases. This innovative approach, OPS-gdT, outperformed conventional therapies in controlling tumor growth in preclinical trials. Learn more about this game-changing development in cancer treatment. #Immunotherapy #CancerResearch #Innovation #UCLResearch

✨Exciting news! ✨ I'm thrilled to share that our research paper - "Fer governs mTORC1 regulating pathways and sustains viability of pancreatic ductal adenocarcinoma cells", has been published in Frontiers in Oncology! This study, conducted in collaboration with Ilan Schrier and Nofar Most Menahem, delves into the critical role of Fer kinase in pancreatic cancer cell survival. Our findings reveal how Fer influences signaling pathways linked to mTORC1, a key player in cancer development. Check out the full article here : https://lnkd.in/gZtW3_Eh #pancreaticcancer #cancerresearch #mTORC1